Marliolide Derivative Induces Melanosome Degradation via Nrf2/p62-Mediated Autophagy.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
13 Apr 2021
Historique:
received: 25 03 2021
revised: 05 04 2021
accepted: 10 04 2021
entrez: 30 4 2021
pubmed: 1 5 2021
medline: 13 5 2021
Statut: epublish

Résumé

Nuclear factor erythroid 2-related factor 2 (Nrf2), which is linked to autophagy regulation and melanogenesis regulation, is activated by marliolide. In this study, we investigated the effect of a marliolide derivative on melanosome degradation through the autophagy pathway. The effect of the marliolide derivative on melanosome degradation was investigated in α-melanocyte stimulating hormone (α-MSH)-treated melanocytes, melanosome-incorporated keratinocyte, and ultraviolet (UV)B-exposed HRM-2 mice (melanin-possessing hairless mice). The marliolide derivative, 5-methyl-3-tetradecylidene-dihydro-furan-2-one (DMF02), decreased melanin pigmentation by melanosome degradation in α-MSH-treated melanocytes and melanosome-incorporated keratinocytes, evidenced by premelanosome protein (PMEL) expression, but did not affect melanogenesis-associated proteins. The UVB-induced hyperpigmentation in HRM-2 mice was also reduced by a topical application of DMF02. DMF02 activated Nrf2 and induced autophagy in vivo, evidenced by decreased PMEL in microtubule-associated proteins 1A/1B light chain 3B (LC3)-II-expressed areas. DMF02 also induced melanosome degradation via autophagy in vitro, and DMF02-induced melanosome degradation was recovered by chloroquine (CQ), which is a lysosomal inhibitor. In addition, Nrf2 silencing by siRNA attenuated the DMF02-induced melanosome degradation via the suppression of p62. DMF02 induced melanosome degradation in melanocytes and keratinocytes by regulating autophagy via Nrf2-p62 activation. Therefore, Nrf2 activator could be a promising therapeutic agent for reducing hyperpigmentation.

Identifiants

pubmed: 33924406
pii: ijms22083995
doi: 10.3390/ijms22083995
pmc: PMC8070456
pii:
doi:

Substances chimiques

Lactones 0
Melanins 0
NF-E2-Related Factor 2 0
Sequestosome-1 Protein 0
marliolide 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : the Start-up Commercialization Project from Small and Medium Business Administration of Korea and by a faculty research grant of Yonsei University College of Medicine
ID : 6-2016-0139

Références

Transl Res. 2018 Mar;193:54-71
pubmed: 29274776
Mol Cell. 2013 Sep 12;51(5):618-31
pubmed: 24011591
PLoS One. 2013 Sep 16;8(9):e75313
pubmed: 24066173
Proc Natl Acad Sci U S A. 2019 Jun 18;116(25):12516-12523
pubmed: 31164420
Redox Biol. 2016 Aug;8:79-90
pubmed: 26765101
J Invest Dermatol. 2011 Nov 17;131(E1):E8-E11
pubmed: 22094404
PLoS One. 2015 Jun 15;10(6):e0129676
pubmed: 26075390
Eur J Med Chem. 2018 Apr 25;150:113-126
pubmed: 29525432
Trends Cell Biol. 2010 Jun;20(6):355-62
pubmed: 20356743
Photochem Photobiol. 2008 May-Jun;84(3):539-49
pubmed: 18435612
J Invest Dermatol. 2014 Aug;134(8):2221-2230
pubmed: 24662764
Mol Med Rep. 2020 Mar;21(3):1421-1430
pubmed: 32016458
Int J Mol Sci. 2016 Jul 15;17(7):
pubmed: 27428965
J Biol Chem. 2011 Apr 8;286(14):12509-23
pubmed: 21317285
Environ Sci Technol. 2013;47(21):12434-40
pubmed: 24094245
EMBO J. 2015 Apr 1;34(7):856-80
pubmed: 25712477
J Invest Dermatol. 2013 Oct;133(10):2416-2424
pubmed: 23558403
Exp Dermatol. 2011 Mar;20(3):242-8
pubmed: 21054558
J Biol Chem. 2003 Jan 24;278(4):2396-402
pubmed: 12441344
Cell. 2008 Jan 11;132(1):27-42
pubmed: 18191218
J Invest Dermatol. 2015 May;135(5):1348-1357
pubmed: 25290687
JAMA Dermatol. 2015 Jul;151(7):722-30
pubmed: 25692384
Pigment Cell Melanoma Res. 2020 May;33(3):403-415
pubmed: 31659857
J Plast Reconstr Aesthet Surg. 2009 Jul;62(7):955-63
pubmed: 18456589
Cell Mol Biol Lett. 2016 Dec 13;21:29
pubmed: 28536631
Pigment Cell Melanoma Res. 2011 Aug;24(4):595-604
pubmed: 21777401
Antioxid Redox Signal. 2010 Dec 1;13(11):1699-712
pubmed: 20486766
Eur J Pharmacol. 2019 Jan 15;843:12-26
pubmed: 30359563
Int J Biochem Cell Biol. 2016 Dec;81(Pt B):375-382
pubmed: 27732890
Annu Rev Pharmacol Toxicol. 2013;53:401-26
pubmed: 23294312
PLoS One. 2014 Apr 24;9(4):e96035
pubmed: 24763530
Expert Rev Dermatol. 2011 Feb 1;6(1):97-108
pubmed: 21572549
J Invest Dermatol. 2011 Jul;131(7):1420-7
pubmed: 21412259
Int J Mol Sci. 2018 Sep 18;19(9):
pubmed: 30231594
J Biol Chem. 2010 Jul 16;285(29):22576-91
pubmed: 20452972
Biochem Biophys Res Commun. 2018 Sep 18;503(4):2306-2311
pubmed: 29966650
Sci Rep. 2016 Jan 27;6:19914
pubmed: 26814135
Biomed Res Int. 2014;2014:832704
pubmed: 25013806

Auteurs

Cheong-Yong Yun (CY)

STEMORE Co. Ltd., Incheon 21983, Korea.

Nahyun Choi (N)

STEMORE Co. Ltd., Incheon 21983, Korea.

Jae Un Lee (JU)

College of Pharmacy, Dongguk University-Seoul, Goyang 10326, Gyeonggi-do, Korea.

Eun Jung Lee (EJ)

Department of Dermatology and Cutaneous Biology Research Institute, Severance Hospital, Yonsei University College of Medicine, Seoul 03722, Korea.
Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul 03722, Korea.

Ji Young Kim (JY)

Department of Dermatology and Cutaneous Biology Research Institute, Severance Hospital, Yonsei University College of Medicine, Seoul 03722, Korea.

Won Jun Choi (WJ)

College of Pharmacy, Dongguk University-Seoul, Goyang 10326, Gyeonggi-do, Korea.

Sang Ho Oh (SH)

Department of Dermatology and Cutaneous Biology Research Institute, Severance Hospital, Yonsei University College of Medicine, Seoul 03722, Korea.

Jong-Hyuk Sung (JH)

STEMORE Co. Ltd., Incheon 21983, Korea.
Institute of Pharmaceutical Sciences, College of Pharmacy, Yonsei University, Incheon 21983, Korea.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH